his.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis
Diabetes Centre, Department of Internal Medicine, Amsterdam University Medical Centres, location VUmc, Amsterdam, Netherlands.
Diabetes Centre, Department of Internal Medicine, Amsterdam University Medical Centres, location VUmc, Amsterdam, Netherlands.
Nephrology and Mineral Metabolism, National Medical Science and Nutrition Institute Salvador Zubirán, Mexico City, Mexico.
University of Texas Southwestern Medical Center, Dallas, TX, United States.
Visa övriga samt affilieringar
2019 (Engelska)Ingår i: Diabetes, obesity and metabolism, ISSN 1462-8902, E-ISSN 1463-1326, Vol. 22, nr 4, s. 549-556Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Aims: Renin-angiotensin system inhibitors (RASi) are the most effective treatments for diabetic kidney disease but significant residual renal risk remains, possibly because of other mechanisms of kidney disease progression unrelated to RAS that may be present. Sodium-glucose co-transporter-2 inhibitors reduce albuminuria and may complement RASi by offering additional renal protection. This post hoc analysis investigated the effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes (T2D) with increased albuminuria treated with or without RASi at baseline. Materials and methods: We evaluated the effects of dapagliflozin 10 mg/day over 12–24 weeks across 13 placebo-controlled studies in patients with T2D with a urinary albumin-to-creatinine ratio (UACR) ≥30 mg/g at baseline. Patients were divided into two subgroups based on treatment with or without RASi at baseline. Results: Compared with patients with RASi at baseline (n = 957), patients without RASi (n = 302) were younger, had a shorter duration of diabetes (7 vs. 12 years), higher estimated glomerular filtration rate (eGFR) and lower UACR, serum uric acid (sUA), body weight and systolic blood pressure. Placebo-adjusted treatment effects of dapagliflozin on UACR, eGFR, glycated haemoglobin and haematocrit over 24 weeks were similar across groups. Mean reductions in body weight and sUA were more distinct in patients without RASi treatment at baseline. Conclusions: Treatment with dapagliflozin over 24 weeks provides similar clinically relevant improvements in metabolic and haemodynamic parameters, and similar reductions in UACR, in patients with T2D with elevated albuminuria treated with or without RASi at baseline. © 2019 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

Ort, förlag, år, upplaga, sidor
John Wiley & Sons, 2019. Vol. 22, nr 4, s. 549-556
Nyckelord [en]
cardiac and renal risk factors, dapagliflozin, RASi, SGLT-2 inhibitors, type 2 diabetes
Nationell ämneskategori
Endokrinologi och diabetes Kardiologi
Forskningsämne
Bioinformatik
Identifikatorer
URN: urn:nbn:se:his:diva-18057DOI: 10.1111/dom.13923ISI: 000518560300009PubMedID: 31742881Scopus ID: 2-s2.0-85076732648OAI: oai:DiVA.org:his-18057DiVA, id: diva2:1382336
Tillgänglig från: 2020-01-02 Skapad: 2020-01-02 Senast uppdaterad: 2020-04-22Bibliografiskt granskad

Open Access i DiVA

fulltext(1221 kB)9 nedladdningar
Filinformation
Filnamn FULLTEXT02.pdfFilstorlek 1221 kBChecksumma SHA-512
a68cc5033076878d1dffd4152c3b290b759f16b27202d811db42435ac64242a0704fec1d491f721b426ff10a2154ab0b9050e129a5383d7760e8471ba9e2660e
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextPubMedScopus

Personposter BETA

Sartipy, Peter

Sök vidare i DiVA

Av författaren/redaktören
Sartipy, Peter
Av organisationen
Institutionen för biovetenskapForskningscentrum för Systembiologi
I samma tidskrift
Diabetes, obesity and metabolism
Endokrinologi och diabetesKardiologi

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 20 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 54 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf